TY - JOUR
T1 - Predictors of inferior clinical outcome in patients with standard-risk multiple myeloma
AU - Badar, Talha
AU - Srour, Samer
AU - Bashir, Qaiser
AU - Shah, Nina
AU - Al-Atrash, Gheath
AU - Hosing, Chitra
AU - Popat, Uday
AU - Nieto, Yago
AU - Orlowski, Robert Z.
AU - Champlin, Richard
AU - Qazilbash, Muzaffar H.
N1 - Publisher Copyright:
© 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd
PY - 2017/3/1
Y1 - 2017/3/1
N2 - Introduction: Outcome of patients with standard-risk (SR) multiple myeloma (MM) has improved; however, subsets of patients do worse than expected. We sought to identify the factors associated with inferior outcome. Methods: We evaluated 51 patients with SR MM that received upfront autologous hematopoietic stem cell transplantation (auto-HCT) after induction and had a progression-free survival (PFS) of ≤18 months. Results: The median age of patients was 61 yr. Forty-one (80%) patients received induction with immunomodulatory drugs, proteosome inhibitors, or combination of both. The overall response rate (ORR) after auto-HCT was 96% (stringent complete response 23%, complete response 10%, very good partial response 22%, and partial response 39%). The median PFS was 7.8, and median overall survival (OS) was 56.3 months. On univariate analysis, concurrent light-chain amyloidosis (AL) was associated with inferior PFS [hematological response (HR); 2.51, 95% CI; 0.64–10.58, P = 0.03] and occurrence of soft tissue plasmacytoma was associated with a significantly shorter OS (HR: 3.05, 95% CI: 0.57–16.29, P = 0.02). Conclusion: Our analysis suggests that concurrent AL and soft tissue plasmacytoma were associated with shorter PFS and OS, respectively. Heterogeneity in clinical outcome of SR MM merits better tools for prognostication, such as gene expression profiling and minimal residual disease assessment to identify high-risk patients.
AB - Introduction: Outcome of patients with standard-risk (SR) multiple myeloma (MM) has improved; however, subsets of patients do worse than expected. We sought to identify the factors associated with inferior outcome. Methods: We evaluated 51 patients with SR MM that received upfront autologous hematopoietic stem cell transplantation (auto-HCT) after induction and had a progression-free survival (PFS) of ≤18 months. Results: The median age of patients was 61 yr. Forty-one (80%) patients received induction with immunomodulatory drugs, proteosome inhibitors, or combination of both. The overall response rate (ORR) after auto-HCT was 96% (stringent complete response 23%, complete response 10%, very good partial response 22%, and partial response 39%). The median PFS was 7.8, and median overall survival (OS) was 56.3 months. On univariate analysis, concurrent light-chain amyloidosis (AL) was associated with inferior PFS [hematological response (HR); 2.51, 95% CI; 0.64–10.58, P = 0.03] and occurrence of soft tissue plasmacytoma was associated with a significantly shorter OS (HR: 3.05, 95% CI: 0.57–16.29, P = 0.02). Conclusion: Our analysis suggests that concurrent AL and soft tissue plasmacytoma were associated with shorter PFS and OS, respectively. Heterogeneity in clinical outcome of SR MM merits better tools for prognostication, such as gene expression profiling and minimal residual disease assessment to identify high-risk patients.
KW - amyloidosis
KW - autologous hematopoietic stem cell transplant
KW - plasmacytoma
KW - standard-risk multiple myeloma
UR - http://www.scopus.com/inward/record.url?scp=85011965793&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85011965793&partnerID=8YFLogxK
U2 - 10.1111/ejh.12826
DO - 10.1111/ejh.12826
M3 - Article
C2 - 27862330
AN - SCOPUS:85011965793
SN - 0902-4441
VL - 98
SP - 263
EP - 268
JO - European Journal of Haematology
JF - European Journal of Haematology
IS - 3
ER -